Potassium

Strong evidence for cardiovascular benefit. A narrow safety margin. Why food, not pills.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In brief: Potassium has strong cardiovascular evidence — lower blood pressure in randomized trials, lower stroke risk in large cohort studies, and direct outcome data from the SSaSS trial — and the benefit comes from food, not pills. Over-the-counter supplements contain no more than 99 mg per dose, far below any therapeutic threshold — a de facto standard rooted in FDA rulings on potassium-chloride drug products — because concentrated potassium can cause dangerous arrhythmias in patients whose kidneys cannot clear it fast enough. Anyone with kidney disease, heart failure, diabetes, or on ACE inhibitors, ARBs, ARNI, or potassium-sparing diuretics needs physician guidance before changing potassium intake through any route, including food and salt substitutes. For everyone else, the DASH dietary pattern is both the evidence and the practical answer.

Introduction

Potassium is the cardiovascular nutrient where the evidence is solid, the mechanism is well-understood, and the supplement aisle is the wrong place to act on it.

Human physiology evolved with high potassium intake and low sodium intake. For most of human history, diets were built around fruits, vegetables, and tubers — potassium-rich, sodium-scarce. The modern processed-food diet has inverted that pattern: large sodium loads, and far less potassium from whole foods. The result is a population consuming roughly 3,400 mg of sodium daily against only about 2,500 mg of potassium — below the recommended intake of 3,400 mg for men and 2,600 mg for women, and far below the 3,500–5,000 mg dietary target the 2017 ACC/AHA guideline sets for blood pressure management. (8,9,11)

The cardiovascular consequences of that inversion are documented across multiple study designs. Randomized trials show meaningful blood pressure reduction when dietary potassium increases. Prospective cohort studies consistently associate higher potassium intake with lower stroke risk. And the Salt Substitute and Stroke Study — a large randomized trial — provided direct evidence that shifting the sodium-potassium balance reduces cardiovascular events and all-cause mortality. The mechanisms are understood and span multiple independent physiological pathways.

What sets potassium apart from every other supplement in this series is the safety constraint. Over-the-counter pills contain no more than 99 mg per dose — a tiny fraction of the several-thousand-milligram dietary intakes that lower blood pressure. That ceiling is a de facto standard, not a packaging accident: it traces to FDA rulings that oral potassium-chloride drug products providing more than 99 mg have been linked to small-bowel injury and must carry warnings, and to the narrow therapeutic window of concentrated potassium, which can cause dangerous arrhythmias in patients with reduced kidney clearance or on common cardiovascular medications. Meaningful supplementation requires a prescription and laboratory monitoring.

The result: potassium’s cardiovascular benefit is real and well-evidenced. Its safety margin is genuinely narrow. The population most likely to benefit from increased intake overlaps substantially with the population most at risk from excess. For people outside that overlap, the answer is dietary. For people inside it, any change to potassium intake is a decision to make with a clinician.

Find Your Situation

The table below identifies what the evidence supports for specific clinical profiles. Each entry is examined fully in the sections that follow.

Why Potassium Matters Clinically

The heart, kidneys, and vascular system depend on maintaining blood potassium within a narrow range. Clinical relevance runs in both directions: too little increases blood pressure, arrhythmia risk, and stroke risk; too much disrupts cardiac electrical activity and can cause arrest. Understanding what potassium does physiologically establishes both why adequate intake matters and why excess is dangerous.

Blood pressure regulation through sodium balance. The most clinically important mechanism. Potassium promotes urinary sodium excretion — a process called natriuresis — by increasing sodium delivery to the kidney tubule segments where sodium and potassium are exchanged. More sodium leaves in urine, less fluid is retained, blood volume falls, and blood pressure decreases. The practical implication is direct: potassium and sodium are physiological counterbalances, each affecting the other’s handling, which is why the ratio between them matters as much as either element alone. (1)

Direct vasodilation. Potassium relaxes vascular smooth muscle by shifting vessel-wall cells toward hyperpolarization — a change in electrical state that makes those cells less likely to contract. The result is lower vascular resistance and lower blood pressure, through normal physiology rather than pharmacological blockade. (1)

Cardiac electrical stability. Potassium is the dominant intracellular ion in cardiac muscle cells. The balance of potassium between the inside and outside of each cell governs the electrical state from which every heartbeat is generated — think of it as the resting charge the heart resets to between beats. Both hypokalemia and hyperkalemia disturb that balance and can trigger arrhythmias — sometimes fatal ones. This is why serum potassium is checked in patients presenting with arrhythmias, and why correcting abnormal levels is part of standard arrhythmia management. (14)

Sympathetic nervous system modulation. Adequate potassium blunts sympathetic nervous system activity — the branch that raises heart rate and promotes vasoconstriction. Deficiency has the opposite effect, contributing to hypertension and arrhythmia risk through an autonomic pathway independent of the sodium-balance mechanism. (1)

Endothelial function and vascular integrity. Potassium supports the endothelium’s capacity to regulate vascular tone, inflammation, and vessel-wall integrity. Endothelial dysfunction is an early feature of atherosclerosis, often present years before clinical events. Adequate potassium intake is associated with better endothelial function in population studies, providing a biologically plausible link from dietary pattern to long-term vascular risk. (1)

Each pathway operates independently, but together they explain why inadequate potassium intake impairs cardiovascular function across multiple dimensions simultaneously — and why correcting it through a dietary pattern addresses all of them at once.

The Clinical Evidence

Blood Pressure: Real and Consistent

A 2017 meta-analysis of randomized controlled trials in hypertensive subjects found that potassium supplementation reduced systolic blood pressure by an average of 4.5 mmHg and diastolic by 3.0 mmHg, with larger effects in those with higher baseline sodium intake. (2) A 2020 dose-response meta-analysis found the blood-pressure benefit was greatest at intakes around 3,500 mg/day (90 mmol), with no further reduction — and some evidence of rising blood pressure — at higher intakes. (6)

To put a 4 to 5 mmHg reduction in practical terms: that is roughly the magnitude of reduction achieved by starting a low-dose thiazide diuretic. At the population level, a sustained systolic reduction of that size is associated, in blood-pressure-lowering meta-analyses, with roughly a 10 to 13% lower stroke risk and about a 7% lower risk of death. (12) The individual benefit is modest; applied consistently across a population, the aggregate effect is substantial.

Stroke Risk: A Consistent Observational Signal

A meta-analysis of prospective cohort studies found that higher potassium intake was associated with lower stroke risk, with the lowest risk at an intake around 3,500 mg/day (90 mmol) — roughly 22% lower than the lowest-intake group — and no further benefit, and a suggestion of reversal, at higher intakes. (10) A broader systematic review confirmed the associations between higher potassium intake and lower rates of stroke, cardiovascular disease, and all-cause mortality across populations. (1) Confounding cannot be eliminated from observational data — people with higher potassium intake also tend to eat more whole foods and follow healthier diets generally. But the consistency across populations with different baseline dietary patterns, and the biological plausibility across multiple independent pathways, make this one of the more credible observational signals in cardiovascular nutrition.

The SSaSS Trial: Direct Outcome Evidence

The Salt Substitute and Stroke Study, published in the New England Journal of Medicine in 2021, randomized 20,995 high-risk adults — prior stroke or age over 60 with uncontrolled hypertension — across 600 rural Chinese villages to either a potassium chloride salt substitute (75% sodium chloride, 25% potassium chloride) or regular salt. (5) Over a mean 4.74 years:

• Stroke reduced by 14%
• Major cardiovascular events reduced by 13%
• All-cause mortality reduced by 12%
• Systolic blood pressure reduced by approximately 3.3 mmHg

No significant excess of clinical hyperkalemia was observed at the population level. Patients with significant kidney disease were excluded from enrollment.

Two interpretive caveats matter. First, the study population had very high baseline sodium intake, where the cardiovascular benefit of shifting the sodium-potassium balance is likely largest; generalizability to populations with already-moderate sodium intake is uncertain. Second, the intervention changed both sodium and potassium at once, so their individual contributions cannot be cleanly separated, though both plausibly contributed. (5)

What this means: The clearest conclusion from SSaSS is that shifting the sodium-potassium balance through a practical dietary change reduces cardiovascular events in high-risk populations, when those populations are not themselves at risk for hyperkalemia.

The DASH Trial: Potassium in Dietary Context

The clearest evidence for dietary potassium’s cardiovascular benefit comes not from isolated potassium supplementation but from the DASH dietary pattern — and what DASH showed clarifies both potassium’s role and its limits.

The original DASH trial found that a diet rich in fruits, vegetables, and low-fat dairy with reduced saturated fat lowered blood pressure by 5.5/3.0 mmHg compared to a typical American diet. In participants with hypertension, the reduction was 11.4/5.5 mmHg — comparable to adding a blood pressure medication. (3) The DASH pattern provides approximately 4,700 mg of potassium daily alongside high magnesium, calcium, and fiber, with reduced sodium. Potassium is a major contributor to the effect, but its specific contribution cannot be separated from the rest of the dietary pattern — and that is the point. The pattern works; potassium is a central reason why; a supplement cannot replicate the full effect.

DASH-Sodium subsequently confirmed that combining the DASH pattern with explicit sodium reduction produced blood pressure reductions larger than either intervention alone. (4)

The Clinical Reframe This Evidence Requires

If you are taking 99 mg OTC potassium pills expecting cardiovascular benefit, the evidence does not support that approach. The blood pressure reductions in these trials were measured at daily intakes of roughly 2,000–4,700 mg — twenty to fifty times the OTC ceiling. The food-based interventions that produced these outcomes cannot be approximated by taking more pills. They are different exposures with different physiological contexts.

Potassium’s Place in Cardiovascular Guidelines

The 2017 ACC/AHA hypertension guideline explicitly recommends increased dietary potassium intake — 3,500–5,000 mg per day, preferably through food — as a non-pharmacologic intervention for blood pressure management in adults with elevated or high blood pressure, with explicit exceptions for those with chronic kidney disease or on potassium-elevating medications. (11) The recommendation is dietary; OTC supplementation is not addressed.

Potassium also carries established roles in specific clinical management contexts within cardiology: replacement during diuretic therapy with documented potassium loss, correction of hypokalemia, and routine serum monitoring in patients on ACE inhibitors, ARBs, ARNI, aldosterone antagonists, or with heart failure or kidney disease. These are physician-managed situations with defined monitoring requirements, not consumer supplement decisions.

The practical distinction: dietary potassium is guideline-recommended for blood pressure management. No guideline recommends OTC potassium supplementation for cardiovascular prevention — because the 99 mg unit cannot deliver doses with cardiovascular effect, and because meaningful potassium dosing requires clinical oversight the OTC context cannot provide.

Supplements vs. Food: Why They Are Not Interchangeable

For most nutrients, choosing food over a supplement is mostly a matter of preference. For potassium, the difference is pharmacological: the same dose behaves differently depending on how it reaches the bloodstream.

The 99 mg OTC Ceiling

Over-the-counter potassium supplements almost universally contain no more than 99 mg of elemental potassium per dosage unit — about 2% of the beneficial dietary intake. This is a de facto industry standard rather than a direct regulatory cap on supplements: by law the FDA generally cannot limit a nutrient’s amount in a dietary supplement except for safety reasons, but manufacturers limit potassium to 99 mg because the FDA has ruled that oral potassium-chloride drug products providing more than 99 mg are associated with small-bowel injury and require warning labels. The practical effect is the same — meaningful supplementation requires medical supervision — and stacking multiple products to work around the 99 mg unit defeats the safety reasoning behind it.

Why Food Is Inherently Safer

Dietary potassium is absorbed gradually as food moves through the digestive tract over several hours. That slow absorption gives the kidneys time to excrete any excess and maintain serum levels within the safe range. Concentrated potassium — particularly when several pills are taken together — can produce a more rapid rise in blood potassium, a clinically meaningful difference in patients with reduced kidney function or on medications that impair excretion. (7) Food-based delivery works within the physiological rhythm of normal kidney handling; bolus doses can work against it.

Prescription Potassium

Higher-dose potassium supplements — typically 10–20 mEq (roughly 400–800 mg) per dose, available as potassium chloride tablets or liquids — require a prescription. These are used to correct documented hypokalemia or to replace diuretic-induced losses, with serum monitoring at appropriate intervals. The prescription requirement exists for the same reason the OTC ceiling does: dose verification, drug interaction screening, and laboratory monitoring matter when the therapeutic window is this narrow.

Salt Substitutes: The Practical Middle Ground

Potassium chloride-based salt substitutes deliver potassium distributed across meals — a more physiologically gradual exposure than concentrated pills — and carry the strongest direct outcome evidence of any approach discussed in this article. SSaSS demonstrated that this approach meaningfully reduces stroke and cardiovascular events in high-risk adults.

One limitation needs plain emphasis: salt substitutes are not appropriate for everyone. People with chronic kidney disease or on ACE inhibitors, ARBs, ARNI, or potassium-sparing diuretics can develop clinically significant hyperkalemia from potassium chloride salt substitutes. The familiar appearance of a table condiment obscures that it delivers meaningful potassium doses — which is precisely why it works for blood pressure, and precisely why it is dangerous in the wrong patient. An additional practical point: real-world use is often liberal. People who switch to potassium chloride salt substitutes may use them more generously than study protocols, delivering more potassium than expected — which matters for anyone in a borderline risk category. (7) Any reader in a high-risk group (detailed in the Safety section below) should discuss salt substitute use with their physician before starting.

High-Potassium Foods: The Practical Path

For readers with hypertension or borderline blood pressure, normal kidney function, and no potassium-elevating medications, consistent dietary increase is both the evidence-based and practically achievable route to cardiovascular benefit. The following are approximate potassium values per typical serving, from the USDA FoodData Central database. (13)

Bananas are the most widely recognized potassium source but not the most efficient: a single banana provides 420 mg — less than half a baked potato, less than a half-cup of white beans, less than a glass of orange juice. Reaching the DASH-level intake of roughly 4,700 mg daily requires deliberate, consistent food choices across most meals. It does not happen automatically on a typical American diet.

The DASH pattern — 8–10 servings of fruits and vegetables daily alongside low-fat dairy, whole grains, and legumes, with reduced sodium and processed food — provides a practical framework for sustaining therapeutic potassium intake. The DASH trials measured blood pressure rather than cardiovascular events, but the pattern is better supported for blood pressure than most supplement approaches in this series, and the closely related salt-substitute trial (SSaSS) extends that evidence to actual cardiovascular events.

Risks, Side Effects, and Toxicity

Potassium has the narrowest safety margin of any nutrient covered in this series. Excess can cause cardiac arrest within hours, particularly in patients with reduced kidney clearance or on medications that retain potassium. The risks are predictable and manageable when understood — but they are concentrated in specific populations, and people in those groups need to recognize that much of the general advice in this article does not apply to them.

Common Side Effects

Oral potassium — OTC and prescription — commonly causes nausea and abdominal discomfort, and can cause esophageal or gastric ulceration if not taken with adequate water. Taking potassium with food and a full glass of water substantially reduces these effects. Slow-release prescription formulations reduce gastrointestinal side effects compared to immediate-release forms. Dietary potassium at high intakes may produce mild osmotic loosening of stools; this is dose-dependent and easily managed.

Hyperkalemia: The Toxicity That Matters

Hyperkalemia — elevated serum potassium — is what distinguishes potassium pharmacologically from most other electrolytes. Unlike most nutrient excess, severe hyperkalemia can cause cardiac arrest within hours of onset. (7,14)

The clinical danger is that early symptoms — weakness, fatigue, nausea, vague tingling — are nonspecific and easily attributed elsewhere. A patient developing hyperkalemia from undisclosed potassium use on top of an ACE inhibitor or mild kidney impairment may have symptoms that no provider connects to potassium until the ECG changes prompt a blood test that reveals the cause. The transition from mild to life-threatening can occur over hours in patients with impaired clearance. (7)

Hypokalemia: The Opposite Problem

Hypokalemia (serum potassium below 3.5 mEq/L) most commonly results from diuretic therapy or gastrointestinal losses and produces muscle weakness, fatigue, palpitations, and arrhythmia risk. It requires prescription potassium repletion under medical supervision with serial serum monitoring. It is not a self-treatment situation — and its treatment is the pharmacological opposite of the treatment for hyperkalemia.

Populations at Elevated Risk for Hyperkalemia

The following groups require physician guidance before any deliberate increase in potassium intake, regardless of route. (7)

Chronic kidney disease (any stage, especially eGFR <60). The eGFR — estimated glomerular filtration rate, a standard blood-test measure of how well the kidneys are filtering — is the primary measure used to classify kidney function. The kidneys are the primary excretion route for potassium, and even modest reductions in function lower the body’s ability to clear a potassium load. At eGFR below 30, dietary potassium restriction is often clinically necessary — foods that are straightforwardly healthy for most people can be dangerous at this level of impairment.

Heart failure with reduced kidney function. These patients are commonly on diuretics (potassium-wasting), ACE inhibitors or ARBs (potassium-retaining), and frequently aldosterone antagonists (strongly potassium-retaining). Net potassium balance varies by patient and clinical state and is managed by the medical team through serum monitoring. Self-modification of potassium intake is not appropriate.

Patients on ACE inhibitors, ARBs, or ARNI (sacubitril/valsartan). All three classes reduce potassium excretion. Adding supplemental potassium, salt substitutes, or aggressive dietary increases on top of these medications can push serum levels into the dangerous range without obvious warning until symptoms appear.

Patients on potassium-sparing diuretics: spironolactone, eplerenone, amiloride, triamterene. These drugs retain potassium as their primary mechanism. Any deliberate increase in potassium intake in combination with these medications carries substantial hyperkalemia risk.

Diabetes. Affects potassium handling through insulin status, kidney effects, and medication interactions — increasing hyperkalemia risk even when formal kidney function tests appear normal.

Older adults. Kidney function declines with age in nearly everyone, often without a formal diagnosis. Many older adults on standard cardiovascular medications carry meaningful hyperkalemia risk that has not been specifically evaluated.

Regular NSAID use. Chronic ibuprofen or naproxen at high doses reduces kidney function and impairs potassium excretion. Combined with ACE inhibitors and a salt substitute, NSAIDs have contributed to symptomatic hyperkalemia in patients who appeared low-risk on any single factor alone.

Drug Interactions

Medications that elevate potassium (increase hyperkalemia risk): ACE inhibitors (lisinopril, enalapril, ramipril, others); ARBs (losartan, valsartan, telmisartan, others); ARNI — sacubitril/valsartan; aldosterone antagonists — spironolactone, eplerenone; potassium-sparing diuretics — amiloride, triamterene; direct renin inhibitors — aliskiren; chronic NSAIDs; trimethoprim-sulfamethoxazole (a common antibiotic that meaningfully elevates potassium); heparin and low-molecular-weight heparin; tacrolimus and cyclosporine; beta-blockers — mild, additive effect.

Medications that lower potassium (increase hypokalemia risk): Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide); loop diuretics (furosemide, bumetanide, torsemide); high-dose beta-2 agonists; rapid insulin administration; theophylline; laxative overuse.

These interactions are predictable — but only manageable when disclosed. A patient on an ACE inhibitor who adds a potassium chloride salt substitute and takes occasional ibuprofen may develop symptomatic hyperkalemia from a combination that no single provider identified as a risk.

When to Seek Medical Attention

Seek emergency evaluation for: sudden or severe muscle weakness; new or significant palpitations; unexplained shortness of breath; a slow or irregular pulse with weakness; confusion or marked drowsiness in someone taking potassium or potassium-affecting medications. These can represent significant hyperkalemia and require immediate evaluation.

Discontinue and contact your prescriber for: persistent nausea or GI distress after starting supplementation or a salt substitute; new muscle weakness coinciding with potassium intake changes; lab-confirmed serum potassium above 5.0 mEq/L.

Absolute contraindications without explicit medical guidance: eGFR below 30 mL/min/1.73m²; acute kidney injury; baseline hyperkalemia (serum potassium above 5.0 mEq/L); concurrent use of multiple potassium-elevating medications without monitoring; active treatment with aldosterone antagonists without monitoring; adrenal insufficiency.

Two Patients, Same Supplement Aisle, Different Answers

Both profiles below are composites built from the populations studied in the trials this article reviews.

Patient A: A 61-year-old man with hypertension on lisinopril, type 2 diabetes well-controlled on metformin, and a most recent eGFR of 72. He eats a typical American processed-food diet and has started using a potassium chloride salt substitute based on a general health article recommending it for blood pressure — without mentioning it to his physician.

This patient is on an ACE inhibitor that reduces potassium excretion. His diabetes independently affects potassium handling. An eGFR of 72 reflects mildly reduced kidney function — not enough to formally categorize him as high-risk under all definitions, but enough to reduce his clearance margin under potassium loading. The SSaSS population excluded patients with significant kidney disease, and its findings do not extend straightforwardly to his profile. Adding a potassium chloride salt substitute on top of lisinopril without monitoring is a meaningful and undisclosed hyperkalemia risk. The defensible action is to stop the salt substitute, inform his physician, check serum potassium, and make a supervised decision about whether and how to incorporate dietary change given his medication and kidney context.

Patient B: A 48-year-old woman with borderline blood pressure averaging 136/84 mmHg, no medications, normal kidney function, and a typical American diet. She asks whether potassium supplements would help.

This patient matches the population in which dietary potassium intervention is guideline-supported and well-evidenced. The evidence-based answer is not OTC supplements — 99 mg pills cannot approach therapeutic doses — but a deliberate shift toward the DASH dietary pattern: more fruits, vegetables, and legumes; less processed food and sodium. A potassium chloride salt substitute is also a reasonable option, ideally with her physician’s awareness. Blood pressure response is expected to emerge over weeks to months of consistent dietary change, and she should monitor it — either at home or at her next clinical visit.

Common Misconceptions

“More potassium is always better.” The dose-response curve for blood pressure benefit plateaus at around 3,500 mg daily (90 mmol). (6) Intake above that provides no additional cardiovascular benefit and increases risk in anyone with impaired clearance.

“OTC potassium pills work for cardiovascular prevention.” At 99 mg per pill, they cannot deliver doses with any cardiovascular effect. The clinical trials demonstrating benefit used daily intakes twenty to fifty times higher. The 99 mg unit is a safety-driven industry standard, not a therapeutic starting point.

“Salt substitutes are safe for everyone.” They are not. People with chronic kidney disease or on ACE inhibitors, ARBs, ARNI, or potassium-sparing diuretics can develop clinically significant hyperkalemia from potassium chloride salt substitutes. A product sold in the seasoning aisle does not carry the safety framing its pharmacological effect warrants.

“Bananas are the best potassium source.” A baked potato contains more than twice the potassium of a banana. A half-cup of canned white beans contains approximately 40% more. Bananas are easy to identify as a potassium source; they are not the most efficient choice for reaching therapeutic intake.

“If I eat a banana daily while on a diuretic, I am replacing what it loses.” Diuretic-induced potassium loss is often significant enough to require prescription repletion with serum monitoring. A banana provides modest incremental potassium — it does not reliably correct clinically meaningful losses from loop or thiazide diuretics.

The Bottom Line

Potassium has genuine, well-replicated cardiovascular evidence: lower blood pressure in randomized trials, reduced stroke risk in large cohort studies, and direct outcome benefit from a well-designed randomized trial. The dietary recommendation sits in major cardiovascular guidelines. The mechanisms are understood and independent of each other. This is not theoretical cardiovascular benefit — it is among the better-evidenced nutritional interventions in this series.

None of that evidence applies to over-the-counter supplements, which cannot deliver therapeutic doses; and it does not straightforwardly apply to patients whose physiology makes any meaningful potassium increase dangerous. For those with hypertension, normal kidney function, and no potassium-elevating medications, the DASH dietary pattern is well-supported and practical. For those with kidney disease, heart failure, diabetes, or on ACE inhibitors, ARBs, ARNI, or potassium-sparing diuretics, changing potassium intake through any route requires physician guidance — because the early signs of hyperkalemia are easy to miss and the consequences are not.

The cardiovascular evidence for potassium is strong, and it points to food rather than pills. For people who can safely raise their intake, potassium is one of the few topics in this series where the evidence-based answer is yes — achieved through diet, not the supplement aisle.

Article 12 examines nitric oxide precursors — beetroot juice, L-arginine, and L-citrulline — where blood pressure effects in hypertensive populations are real and measurable, and where the reason these supplements disappoint in established cardiovascular disease comes down to what providing more raw material cannot fix.

Key Terms

ACE inhibitors: Angiotensin-converting enzyme inhibitors, including lisinopril, enalapril, and ramipril. Reduce potassium excretion as part of their mechanism, increasing hyperkalemia risk when potassium intake increases.

Aldosterone antagonists: Medications including spironolactone and eplerenone that block the hormone aldosterone, retaining potassium as their primary effect. Used in heart failure and resistant hypertension; carry substantial hyperkalemia risk when combined with any deliberate potassium increase.

ARBs (Angiotensin Receptor Blockers): Including losartan, valsartan, and telmisartan. Similar potassium-retaining effects to ACE inhibitors.

ARNI (Angiotensin Receptor-Neprilysin Inhibitor): Sacubitril/valsartan (brand name Entresto), used in heart failure. Carries the same potassium-retaining risk as ACE inhibitors and ARBs.

DASH diet: Dietary Approaches to Stop Hypertension. A dietary pattern proven in randomized trials to substantially lower blood pressure through high intake of fruits, vegetables, low-fat dairy, whole grains, and legumes with reduced sodium. Provides approximately 4,700 mg of potassium daily.

Hyperkalemia: Abnormally elevated blood potassium (above 5.0 mEq/L). Early symptoms are nonspecific; severe hyperkalemia causes progressive cardiac conduction disturbances and can result in cardiac arrest.

Hyperpolarization: A shift in a cell’s electrical state that reduces its likelihood of contracting — the mechanism by which potassium relaxes vascular smooth muscle and produces vasodilation.

Hypokalemia: Low blood potassium (below 3.5 mEq/L). Causes muscle weakness, fatigue, and arrhythmia risk. Most commonly results from diuretic therapy or gastrointestinal losses; requires prescription repletion under medical supervision.

Natriuresis: Urinary excretion of sodium. Potassium promotes natriuresis through a tubular exchange mechanism in the kidney — the primary physiological pathway linking dietary potassium to blood pressure reduction.

Peaked T waves: The earliest electrocardiographic sign of hyperkalemia — tall, narrow T waves — typically appearing when serum potassium exceeds approximately 5.5 mEq/L.

Potassium-sparing diuretics: Diuretics that promote sodium excretion while retaining potassium. Includes aldosterone antagonists (spironolactone, eplerenone) and direct sodium channel blockers (amiloride, triamterene).

Sodium-potassium ratio: The balance between dietary sodium and potassium intake. Both DASH-Sodium and SSaSS demonstrate that correcting an adverse ratio — high sodium, low potassium — reduces blood pressure and cardiovascular events.

SSaSS: The Salt Substitute and Stroke Study. Published in the New England Journal of Medicine in 2021; 20,995 high-risk Chinese adults randomized to potassium chloride salt substitute versus regular salt. Stroke reduced by 14%, major cardiovascular events by 13%, all-cause mortality by 12%, over a mean 4.74 years.

References

1. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378.
2. Filippini T, Violi F, D’Amico R, Vinceti M. The effect of potassium supplementation on blood pressure in hypertensive subjects: a systematic review and meta-analysis. Int J Cardiol. 2017;230:127–135.
3. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure (DASH). N Engl J Med. 1997;336(16):1117–1124.
4. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3–10.
5. Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death (SSaSS). N Engl J Med. 2021;385(12):1067–1077.
6. Filippini T, Naska A, Kasdagli MI, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(12):e015719.
7. Palmer BF, Clegg DJ. Achieving the benefits of a high-potassium, paleolithic diet, without the toxicity. Mayo Clin Proc. 2016;91(4):496–508.
8. Weaver CM. Potassium and health. Adv Nutr. 2013;4(3):368S–377S.
9. National Academies of Sciences, Engineering, and Medicine. Dietary Reference Intakes for Sodium and Potassium. Washington, DC: National Academies Press; 2019.
10. Vinceti M, Filippini T, Crippa A, et al. Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc. 2016;5(10):e004210.
11. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
12. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–967.
13. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central. https://fdc.nal.usda.gov.
14. Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18(6):721–729.

HeartBuddi • Your heart. Own it.